Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies

Gurkan, Umut A.; Wood, David K.; Carranza, Dorn; Herbertson, Luke H.; Diamond, Scott L.; Du, E.; Guha, Suvajyoti; Di Paola, Jorge; Hines, Patrick C.; Papautsky, Ian; Shevkoplyas, Sergey S.; Sniadecki, Nathan J.; Pamula, Vamsee K.; Sundd, Prithu; Rizwan, Asif; Qasba, Pankaj; Lam, Wilbur A.

doi:10.1039/d3lc00796k

Cited by 14 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microfluidic devices offer a substantial reduction in reagent consumption, chemical reaction durations, and overall costs through integration on a single chip. This advancement holds the potential to facilitate innovative point-of-care (POC) and pointof-need solutions for clinical diagnostics (Gurkan et al, 2024).…”

Section: Introductionmentioning

confidence: 99%

Progress and application of lung-on-a-chip for lung cancer

Li,

Bo,

Wang

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Lung cancer is a malignant tumour with the highest incidence and mortality worldwide. Clinically effective therapy strategies are underutilized owing to the lack of efficient models for evaluating drug response. One of the main reasons for failure of anticancer drug therapy is development of drug resistance. Anticancer drugs face severe challenges such as poor biodistribution, restricted solubility, inadequate absorption, and drug accumulation. In recent years, “organ-on-a-chip” platforms, which can directly regulate the microenvironment of biomechanics, biochemistry and pathophysiology, have been developed rapidly and have shown great potential in clinical drug research. Lung-on-a-chip (LOC) is a new 3D model of bionic lungs with physiological functions created by micromachining technology on microfluidic chips. This approach may be able to partially replace animal and 2D cell culture models. To overcome drug resistance, LOC realizes personalized prediction of drug response by simulating the lung-related microenvironment in vitro, significantly enhancing therapeutic effectiveness, bioavailability, and pharmacokinetics while minimizing side effects. In this review, we present an overview of recent advances in the preparation of LOC and contrast it with earlier in vitro models. Finally, we describe recent advances in LOC. The combination of this technology with nanomedicine will provide an accurate and reliable treatment for preclinical evaluation.

show abstract

Section: Introductionmentioning

confidence: 99%

Progress and application of lung-on-a-chip for lung cancer

Li,

Bo,

Wang

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

Application and progress of 3D tumor models in breast cancer

Xu,

Fang,

Zhou

et al. 2024

Biotech & Bioengineering

View full text Add to dashboard Cite

Due to its high heterogeneity and significant impact on women's health globally, breast cancer necessitates robust preclinical models to understand tumor biology and guide personalized treatment strategies. Three‐dimensional (3D) in vitro tumor models hold immense promise in this regard. These tumor models not only mimic the spatial structure and growth environment of tumors in vivo, but also retain the pathological and genetic characteristics of solid tumors. This fidelity makes them powerful tools for accelerating advancements in fundamental research and translational medicine. The diversity, modularity, and efficacy of 3D tumor models are driving a biotechnological revolution. As these technologies become increasingly sophisticated, 3D tumor models are poised to become powerful weapons in the fight against breast cancer. This article expounds on the progress made in utilizing 3D tumor models for breast cancer research.

show abstract